US Broker Ratings

AptarGroup, Inc. (ATR) Stock Analysis: Healthcare Innovator with a 24.98% Potential Upside

AptarGroup, Inc. (NYSE: ATR), a leader in the healthcare sector, is making waves with its innovative solutions for drug delivery and consumer product dispensing. With a market cap of $8.45..

Bio-Techne Corp (TECH) Investor Outlook: Evaluating its Steady Path in Biotechnology with a Focus on Stability

Bio-Techne Corp (NASDAQ: TECH) stands as a significant player in the biotechnology space, boasting a market cap of $11.16 billion. Known for developing and manufacturing life science reagents, instruments, and..

Regencell Bioscience Holdings (RGC) Stock Analysis: Navigating Volatility in Healthcare Innovation

Regencell Bioscience Holdings Limited (NASDAQ: RGC) is making waves in the healthcare sector, specifically within the niche of traditional Chinese medicine (TCM). With a market capitalization of $2.83 billion, this..

Revolution Medicines, Inc. (RVMD) Stock Analysis: Biotechnology Innovator with Strong Buy Ratings and Upside Potential

Revolution Medicines, Inc. (NASDAQ: RVMD) is making waves in the healthcare sector, specifically within the biotechnology industry, with its innovative approach to precision oncology. Headquartered in Redwood City, California, this..

Tempus AI, Inc. (TEM) Stock Analysis: Exploring the 55.94% Potential Upside and Analyst Ratings

As Tempus AI, Inc. (NASDAQ: TEM) continues to innovate in the healthcare technology arena, individual investors are keenly evaluating its potential as an investment. With a market capitalization of $7.69..

The Ensign Group, Inc. (ENSG) Stock Analysis: A Healthcare Giant Poised for 25.90% Upside

The Ensign Group, Inc. (NASDAQ: ENSG), a major player in the healthcare sector with a market capitalization of $10.11 billion, is capturing investor attention with its substantial growth potential. Trading..

Stevanato Group S.p.A. (STVN) Stock Analysis: A Healthcare Giant with a 24.24% Upside Potential

For investors seeking exposure in the healthcare sector, Stevanato Group S.p.A. (NYSE: STVN) presents a compelling opportunity. With its broad range of products and services catering to the biopharma and..

Atrium Therapeutics, Inc. (RNA) Stock Analysis: Exploring a 117.58% Potential Upside in Biotech

Atrium Therapeutics, Inc. (NASDAQ: RNA), a promising player in the biotechnology sector, is capturing investor attention with its significant potential upside, pegged at 117.58%. Specializing in RNA therapeutics aimed at..

Elanco Animal Health (ELAN) Stock Analysis: Uncovering a 20.72% Upside Potential

Elanco Animal Health Incorporated (NYSE: ELAN), a key player in the healthcare sector, specifically within the drug manufacturing space for specialty and generic products, has been making waves with its..

Vaxcyte, Inc. (PCVX) Stock Analysis: A 99% Potential Upside in a Clinical-Stage Vaccine Innovator

Investors with an eye on the biotechnology sector may find Vaxcyte, Inc. (NASDAQ: PCVX) an intriguing opportunity, particularly with analysts projecting a potential upside of nearly 100%. As a clinical-stage..

Illumina, Inc. (ILMN) Stock Analysis: Navigating Growth and Volatility in the Genomics Sector

As a prominent player in the genomics sector, Illumina, Inc. (NASDAQ: ILMN) has carved out a significant niche with its cutting-edge sequencing and array-based solutions. For investors, the company offers..

Penumbra, Inc. (PEN) Stock Analysis: Exploring Growth Potential and Analyst Consensus for Investors

Penumbra, Inc. (NYSE: PEN), a leading player in the healthcare sector specializing in medical devices, has emerged as a noteworthy consideration for investors seeking exposure to innovative medical technologies. With..

Madrigal Pharmaceuticals (MDGL) Stock Analysis: Exploring a 24.82% Potential Upside in the Biotech Sector

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has emerged as a prominent player in the biotechnology sector, with its focus on innovative treatments for metabolic dysfunction-associated steatohepatitis (MASH). The company’s flagship product,..

TG Therapeutics, Inc. (TGTX) Stock Analysis: A Biotech Powerhouse with a 14.2% Potential Upside

TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company at the forefront of developing innovative treatments for B-cell mediated diseases, has captured the attention of investors with its strong market presence..

Krystal Biotech, Inc. (KRYS) Stock Analysis: Biotechnology Pioneer with 12.40% Potential Upside

Krystal Biotech, Inc. (NASDAQ: KRYS) is increasingly capturing the attention of investors in the biotechnology sector. With its impressive portfolio of genetic medicines targeting diseases with significant unmet medical needs,..

Telix Pharmaceuticals Limited (TLX): Navigating a 105% Potential Upside with Innovative Radiopharmaceuticals

Telix Pharmaceuticals Limited (TLX) is carving a niche in the biopharmaceutical sector with its innovative approach to therapeutic and diagnostic radiopharmaceuticals. As a commercial-stage company, Telix is focused on developing..

Cytokinetics, Incorporated (CYTK) Stock Analysis: Unveiling a 33.51% Potential Upside in Biotechnology

Cytokinetics, Incorporated (NASDAQ: CYTK) stands out in the biotechnology sector with its innovative approach to developing treatments for muscle-related diseases. The company’s singular focus on muscle activators and inhibitors presents..

Agilent Technologies, Inc. (A) Stock Analysis: Exploring a 14.97% Upside Potential

Agilent Technologies, Inc. (NYSE: A), a key player in the healthcare sector, stands as a compelling investment opportunity in the diagnostics and research industry. With a robust market capitalization of..

Corcept Therapeutics (CORT) Stock Analysis: Unveiling a Potential 11.16% Upside in Biotech

Corcept Therapeutics Incorporated (NASDAQ: CORT), a prominent player in the biotechnology sector, has been capturing investor attention with its promising pipeline of medications targeting severe endocrinologic and oncologic disorders. Headquartered..

Oscar Health, Inc. (OSCR) Stock Analysis: Navigating Growth with a 52.60% Revenue Surge

Oscar Health, Inc. (NYSE: OSCR) is making waves in the healthcare sector with its impressive revenue growth, capturing the attention of savvy investors. With the company reporting a staggering 52.60%..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds